Organotin compounds such as tributyltin (TBT) and triphenyltin (TPT) are frequent environmental contaminants and are suspected of disrupting endocrine function in vertebrates and invertebrates. Previously, we reported that TBT and TPT function as powerful agonists for peroxisome proliferator-activated receptor (PPAR) gamma and stimulate adipocyte differentiation via the PPARgamma signaling pathway. Our current study investigates the structure-dependent binding of butyltin and phenyltin compounds to PPARgamma and their ability to activate the receptor. A Scatchard analysis with purified recombinant PPARgamma demonstrated that [(14)C]TPT binds to PPARgamma with an equilibrium dissociation constant (K(d)) of 66.6+/-5.2 nM, which approximated the 46.2+/-2.5 nM K(d) of a typical PPARgamma agonist, [(3)H]rosiglitazone (Rosi). TBT, TPT, diphenyltin (DPT), and tetrabutyltin (TeBT) blocked the binding of [(3)H]Rosi to PPARgamma in a competitive manner, and all tested organotin compounds except monobutyltin blocked the binding of [(14)C]TPT to PPARgamma in a competitive manner. Unexpectedly, Rosi did not compete at all with [(14)C]TPT for binding to PPARgamma, and contrary to the results of the competition assay, TBT and TeBT, but not dibutyltin, transcriptionally activated a GAL-PPARgamma chimeric receptor. All tested phenyltin compounds transcriptionally activated GAL-PPARgamma with an order of potency of TPT>DPT>monophenyltin. In addition, treatment of human choriocarcinoma cells with TBT, TeBT, and all tested phenyltin compounds stimulated production of human chorionic gonadotropin, which is upregulated by PPARgamma-mediated transcription. Our observations indicate that trialkylated and triphenylated tin compounds are the most potent PPARgamma agonists among the alkylated and phenylated tin compounds, and a phenyl substituent on a tin atom enhances the potency of organotin compounds as a PPARgamma agonist much more than a butyl substituent.